secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2025-11-17T23:59:59+00:00
Accession:  0001193125-25-283861
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

4D Molecular Therapeutics appoints Kristian Humer as CFO effective Nov 17, 2025
-------------------------------------------------------------------------------

- Kristian Humer, formerly CFO at Foghorn Therapeutics and Viridian Therapeutics, joins as CFO and Principal Financial Officer.
- Compensation includes $520K base salary, 40% target bonus, option for 480K shares, and $100K sign-on bonus paid in two installments.
- Severance: 9 months base salary + COBRA if terminated w/o cause or for good reason; 12 months + COBRA plus full equity acceleration if within 12 months of a change in control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000119312525283861/0001193125-25-283861-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000119312525283861/d14139d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-283861

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer